Archive · 21 Jul 2026
Weight-Loss Drugs for Overweight Pets
Many cats and dogs in the US are overweight, which can lead to health problems like diabetes and heart disease.
Scientists are testing new drugs, similar to Ozempic for humans, to help pets lose weight.
These drugs come in the form of small implants that release medicine slowly over six months.
Companies like OKAVA Pharmaceuticals and Akston Biosciences are working on these treatments to make it easier for pets to stay healthy without changing their feeding routines.
The goal is to improve the lives of overweight pets and help them live longer.
61% of cats and 59% of dogs in the US are classified as obese.
GLP-1 drugs like OKV-119 are being tested for pets to help with weight loss.
OKAVA Pharmaceuticals is developing a six-month implant for cats and dogs.
Akston Biosciences is conducting a clinical trial for overweight cats.
Target breeds for dogs include pugs, beagles, and labradors.
- Who
- Veterinarians, biotech firms like OKAVA Pharmaceuticals, Akston Biosciences, and Vivani Medical
- What
- Development and testing of GLP-1 drugs for overweight pets
- When
- Currently in early-stage clinical trials
- Where
- United States
- Why
- To address pet obesity and its associated health risks
Proponents of Pet Weight-Loss Drugs
Critics of Pet Weight-Loss Drugs
Effectiveness and Convenience
Proponents of Pet Weight-Loss Drugs
Proponents argue that GLP-1 drugs like OKV-119 are effective in managing pet obesity and offer a convenient, long-lasting solution with implants that last up to six months.
Critics of Pet Weight-Loss Drugs
Critics may question the long-term safety and efficacy of these drugs, emphasizing the need for more extensive clinical trials and potential side effects.
Health Benefits
Proponents of Pet Weight-Loss Drugs
Supporters highlight the health benefits, such as reduced risk of diabetes, arthritis, and heart disease, and improved lifespan for pets.
Critics of Pet Weight-Loss Drugs
Opponents might argue that natural methods like diet and exercise should be prioritized over pharmaceutical interventions, citing potential risks and unknown long-term effects.
- Percentage of Overweight Pets
- 61% of cats and 59% of dogs in the US are classified as obese.
- Company Testing Implants
- OKAVA Pharmaceuticals
- Drug Name
- OKV-119
- Duration of Implant
- Up to six months
- Clinical Trial for Cats
- MEOW-1 clinical trial by Akston Biosciences
- Target Breeds for Dogs
- Pugs, beagles, and labradors